These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31848740)

  • 1. Elderly-onset Crohn's disease remarkably responsive to ustekinumab: a case report.
    Iwamoto M; Kato K; Moriyama M
    Int J Colorectal Dis; 2020 Feb; 35(2):355-359. PubMed ID: 31848740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
    Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
    Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn's disease.
    Okuda H; Hosomi S; Itani S; Kurimoto N; Kobayashi Y; Nakata R; Nishida Y; Ominami M; Nadatani Y; Fukunaga S; Otani K; Kamata N; Tanaka F; Nagami Y; Taira K; Ohfuji S; Fujiwara Y
    J Gastroenterol Hepatol; 2023 Jun; 38(6):910-920. PubMed ID: 36807301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.
    Barkai LJ; Gonczi L; Balogh F; Angyal D; Farkas K; Farkas B; Molnar T; Szamosi T; Schafer E; Golovics PA; Juhasz M; Patai A; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Szekely H; Miheller P; Lakatos PL; Ilias A
    Sci Rep; 2024 Jun; 14(1):14909. PubMed ID: 38942890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
    Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
    J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
    [No Abstract]   [Full Text] [Related]  

  • 6. Ustekinumab for the treatment of Crohn's disease.
    Hansen T; Targownik LE
    Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2023 Jul; 29(7):1015-1023. PubMed ID: 35920382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn's disease with upper gastrointestinal involvement in a biologic-experienced individual.
    Yu N; Sarwal D; Ash R; Aslinia FM
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34645625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post-marketing surveillance in Japan.
    Yokoyama S; Asano T; Nagano K; Tsuchiya H; Takagishi M; Tsujioka S; Miura N; Matsumoto T
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3069-3076. PubMed ID: 34180096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
    Kassouri L; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Dig Liver Dis; 2020 Oct; 52(10):1148-1155. PubMed ID: 32828693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab: a novel therapeutic option in Crohn's disease.
    Simon EG; Samuel S; Ghosh S; Moran GW
    Expert Opin Biol Ther; 2016 Aug; 16(8):1065-74. PubMed ID: 27341173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.
    Pan Y; Ahmed W; Mahtani P; Wong R; Longman R; Jeremy Lukin D; Scherl EJ; Battat R
    Inflamm Bowel Dis; 2022 Dec; 28(12):1865-1871. PubMed ID: 35212368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab as the First Biological Agent for Crohn's Disease in a 10-Year-Old Girl.
    Fujita Y; Sugaya T; Tanaka T; Tominaga K; Yoshihara S
    Tohoku J Exp Med; 2021 Sep; 255(1):57-60. PubMed ID: 34588346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of ustekinumab in elderly Crohn's disease patients.
    Fiske J; Liu E; Limdi JK; Conley TE; Townsend T; Davies M; Brockwell R; Baig D; Abdelbadiee S; Uney A; Liaros A; Gaba W; Smith PJ; Flanagan PK; Subramanian S
    Eur J Gastroenterol Hepatol; 2022 Nov; 34(11):1132-1139. PubMed ID: 36170682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
    Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
    Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.
    Kawalec P; Moćko P; Malinowska-Lipien I; Brzostek T
    J Comp Eff Res; 2017 Oct; 6(7):601-612. PubMed ID: 28660802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
    Ten Bokkel Huinink S; Biemans V; Duijvestein M; Pierik M; Hoentjen F; West RL; van der Woude CJ; de Vries AC
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e783-e788. PubMed ID: 34334713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.